Incidence and mortality of post‐transplant lymphoproliferative disorders after kidney transplantation: A real‐world retrospective analysis in Japan

2021 ◽  
Author(s):  
Taigo Kato ◽  
Takahiro Yoshida ◽  
Ayumu Taniguchi ◽  
Masataka Kawamura ◽  
Shigeaki Nakazawa ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Retrospective Analysis ◽  
Real World ◽  
Lymphoproliferative Disorders ◽  
Post Transplant ◽  
Incidence And Mortality

Oral Post-Transplant Lymphoproliferative Disorders After Kidney Transplantation

2015 ◽  
Vol 120 (2) ◽  
pp. e37
Author(s):  
ANA CAROLINA AMORIM PELLICIOLI ◽  
ALINE ALVES LUCIANO ◽  
ANA LÚCIA CARRINHO AYROZA RANGEL ◽  
GREISON RABELO DE OLIVEIRA ◽  
OSLEI PAES DE ALMEIDA ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Lymphoproliferative Disorders ◽  
Post Transplant

Post-transplant lymphoproliferative disorders in kidney transplantation: histological and molecular genetic assessment

2002 ◽  
Vol 16 (s8) ◽  
pp. 12-17 ◽  
Author(s):  
Junki Koike ◽  
Yutaka Yamaguchi ◽  
Masahiro Hoshikawa ◽  
Hiroko Takahashi ◽  
Shigeru Horita ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Molecular Genetic ◽  
Lymphoproliferative Disorders ◽  
Post Transplant ◽  
Genetic Assessment

Post-Transplant Lymphoproliferative Disorders after Heart or Kidney Transplantation at a Single Centre: Presentation and Response to Treatment

2008 ◽  
Vol 120 (1) ◽  
pp. 36-46 ◽  
Author(s):  
S.M.L. Aversa ◽  
S. Stragliotto ◽  
D. Marino ◽  
F. Calabrese ◽  
P. Rigotti ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Lymphoproliferative Disorders ◽  
Response To Treatment ◽  
Single Centre ◽  
Post Transplant

MO952EFFECT OF KIDNEY TRANSPLANTATION ON PARATHYROID GLANDS FUNCTION

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Maria Ivanova ◽  
Olga Vetchinnikova ◽  
Andrey Vatazin
Keyword(s):  
Kidney Transplantation ◽  
Retrospective Analysis ◽  
Kidney Transplant ◽  
Graft Function ◽  
Early Postoperative Period ◽  
Parathyroid Glands ◽  
Kidney Graft ◽  
Post Transplant ◽  
Transplant Function ◽  
Serum Pth

Abstract Background and Aims The normalization of the function of the parathyroid glands after successful kidney transplantation does not occur in all patients. The aim of our study was to determine of parathyroid function, patient factors that would be predictive of achieving a normal serum PTH in the first months after surgery and prevalence of hyperparathyroidism (HPT) in patients after kidney transplantation (KT) at various stages of the post-transplant period. Method The observational cross-retrospective study included 230 kidney graft recipients. Inclusion criteria: the duration of the post-transplant period is more than 12 months and stable kidney transplant function for 6 months. The median of the pre-transplant stage was 18 months (Q1-Q3: 9; 35), post-transplant period - 42 months (Q1-Q3: 21; 73). Serum concentrations of parathyroid hormone (PTH), calcium, phosphorus, total alkaline phosphatase activity, albumin, and creatinine were determined using standard methods. HPT was diagnosed with PTH>130 pg/ml. Retrospective analysis of parameters in three months after surgery it was performed in 197 patients. Estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI formula, stratification of chronic kidney disease (CKD) stages was carried out according to the eGFR. Results Patients had different kidney transplant function: eGFR 117-15 ml/min, median 51 (Q1-Q3: 39;65): CKD 1(КT) st. was in 3.5%, CKD 2(КT) st. - in 33.9%, CKD 3(КT) st. - in 49.1% and CKD 4(КT) st. – in 13.5% patients. Serum PTH levels were 27-670 pg/ml, median 120 pg/ml (Q1-Q3: 87; 182). The median PTH of blood in patients was 99 pg/ml (Q1-Q3: 76; 120), 98 pg/ml (Q1-Q3: 79; 123), 120 pg/ml (Q1-Q3: 89; 180) and 267 pg/ml (Q1-Q3: 170; 328), respectively, with CKD 1(КT), CKD 2(КT), CKD 3(T) and CKD 4(КT) st. The frequency of HPT was 38.7%: 19.8% in patients with eGFR≥60 ml/min, 38.1% and 93.5% in patients with CKD 3(КT) and CKD 4(КT) st. (p<0.001) (Fig. 1). HPT was equally frequently diagnosed in the second, third, fourth and fifth years after kidney transplantation and amounted to 30.3% in the first five years. In patients with a post-transplant period of more than 5 years, HPT was 54.7% (p<0.001). In the same group, the proportion of patients with eGFR<60 ml/min was also higher - 55.5% (p=0.002) (Fig. 2). An inverse relationship was established between serum PTH and eGFR and a direct relationship between serum PTH and serum creatinine (p<0.001). A retrospective analysis showed that 3 months after kidney transplantation, the median PTH was 178 pg/ml (Q1-Q3: 120; 250), HPT was recorded in 65.5% of patients. Serum PTH decreased by 6-92%, median 50%. Kidney graft function was worse in patients with a decrease in serum PTH ≤50% (n = 100) versus patients with a decrease in serum PTH >50% (n = 97). Minimal blood creatinine was recorded in the early postoperative period, respectively, on (median) 7 and 5 days (p = 0.015), the median eGFR by the end of the third month was 59 and 63 ml/min, respectively (p=0.044). We found that preoperative PTH>585 pg/ml (p<0.0001 OR 2.93 95% CI 1.78; 5.05), delayed kidney graft function (p=0.005 OR 1.57 95% CI 1.58; 9.87), and eGFR<60 ml/min (p<0.0005 OR 2.01 95% CI 1.36; 3.09) were predictive of HPT in patients in the early stages after kidney transplantation. Conclusion Hyperparathyroidism in patients after kidney transplantation continues to be an ongoing problem. It occurs in a third of patients in the first five postoperative years and in half patients in subsequent years. Preoperative secondary hyperparathyroidism, delayed and suboptimal kidney graft function prevent the restoration of parathyroid glands function after kidney transplantation.

scholarly journals Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT

2021 ◽  
Author(s):  
Toby A. Eyre ◽  
Sophie Caillard ◽  
Herve Finel ◽  
Ariane Boumendil ◽  
Jaimal Kothari ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Retrospective Analysis ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Lymphoproliferative Disorders ◽  
Published Data ◽  
High Dose ◽  
Solid Organ ◽  
Post Transplant

AbstractPublished data describing the efficacy and safety of autologous stem-cell transplantation (autoSCT) in post-transplant lymphoproliferative disorders (PTLD) is limited to case reports. This is a retrospective analysis of 21 patients reported to the EBMT registry who received an autoSCT for PTLD post solid organ transplant (SOT). Median age at autoSCT was 47 (range: 22–71) years. The commonest SOTs were kidney (48%) and liver (24%). Commonest histologies included DLBCL-type PTLD (14/21) and plasmacytoma-like PTLD (3/21). Patients received a median of two lines of therapy (range: 1–4) pre-autoSCT. ECOG performance status pre-autoSCT was 0 in 14% and 1 in 86%. Remission status pre-autoSCT was CR 47% and PR 38%. BEAM conditioning was used in 57% and high-dose melphalan in 10%. The median follow-up post-autoSCT was 64 months for alive patients. 3-year PFS was 62% [95% confidence interval (CI) 44–87%] and 3-year OS was 61% [95% CI:43–86]. There were 12 deaths, including four related to autoSCT. 100-day non-relapse-mortality (NRM) was 14% and 1-year NRM was 24%. This study suggests that autoSCT, although feasible and with potential therapeutic activity, is associated with a high NRM, primarily driven by infectious toxicity. A multi-disciplinary approach, expert microbiological input and stringent patient selection are required to optimise outcomes.

scholarly journals Current Pharmacological Intervention and Medical Management for Diabetic Kidney Transplant Recipients

Pharmaceutics ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 413
Author(s):  
Theerawut Klangjareonchai ◽  
Natsuki Eguchi ◽  
Ekamol Tantisattamo ◽  
Antoney J. Ferrey ◽  
Uttam Reddy ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Kidney Transplantation ◽  
Kidney Transplant ◽  
Pharmacological Intervention ◽  
Diabetic Patients ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Kidney Allograft ◽  
Post Transplant ◽  
Glucose Management

Hyperglycemia after kidney transplantation is common in both diabetic and non-diabetic patients. Both pretransplant and post-transplant diabetes mellitus are associated with increased kidney allograft failure and mortality. Glucose management may be challenging for kidney transplant recipients. The pathophysiology and pattern of hyperglycemia in patients following kidney transplantation is different from those with type 2 diabetes mellitus. In patients with pre-existing and post-transplant diabetes mellitus, there is limited data on the management of hyperglycemia after kidney transplantation. The following article discusses the nomenclature and diagnosis of pre- and post-transplant diabetes mellitus, the impact of transplant-related hyperglycemia on patient and kidney allograft outcomes, risk factors and potential pathogenic mechanisms of hyperglycemia after kidney transplantation, glucose management before and after transplantation, and modalities for prevention of post-transplant diabetes mellitus.

scholarly journals Real-World Fetal Exposure to Acne Treatments in the United States: A Retrospective Analysis from 2006 to 2015

Drug Safety ◽  
2021 ◽  
Vol 44 (4) ◽  
pp. 447-454 ◽  
Author(s):  
Yasser Albogami ◽  
Amir Sarayani ◽  
Juan M. Hincapie-Castillo ◽  
Almut G. Winterstein
Keyword(s):  
United States ◽  
Retrospective Analysis ◽  
Real World ◽  
The United States ◽  
Fetal Exposure
Sign in / Sign up

Export Citation Format

Share Document